Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease.
Although the pathogenesis of Alzheimer's disease (AD) is still not fully understood, it is acknowledged that intervention should be made at the early stage. Therefore, identifying biomarkers for the clinical diagnosis is critical. Metabolomics, a novel "omics", uses methods based on low-molecular-weight molecules, with high-throughput evaluation of a large number of metabolites that may lead to the identification of new disease-specific biomarkers and the elucidation of pathophysiological mechanisms. This review discusses metabolomics investigations of AD and potential future developments in this field.
Department of Neurology and Institute of Neurology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Xu-Hua
XH
Xu
Yue
Y
Huang
Gang
G
Wang
Sheng-Di
SD
Chen
D000544:Alzheimer Disease / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D055432:Metabolomics / Q000379:methods* / Q000639:trends
D015415:Biomarkers